NCT04221217View on ClinicalTrials.gov

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions
Hypertriglyceridemia
Interventions
DRUG

Icosapent

Icosapent (MND-2119) capsules.

Trial Locations (1)

Unknown

Mochida Investigational sites, Tokyo

Sponsors
All Listed Sponsors
lead

Mochida Pharmaceutical Company, Ltd.

INDUSTRY

NCT04221217 - Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia | Biotech Hunter | Biotech Hunter